Key result
Advanced NSCLC in men is linked to ~21% lower pretreatment serum IGF-1 levels versus controls.
Why the study?
The clinical significance of pretreatment serum levels of IGF-1 and IGFBP-3 in advanced stage NSCLC and their contribution to clinical evaluations was unclear.
Are pretreatment serum levels of IGF-1 and IGFBP-3 altered in men with advanced non-small cell lung cancer compared to healthy controls?
Population
80 men with smoking history of minimum 20 pack/years including 50 advanced stage NSCLC patients and 30 healthy controls
Comparison
Advanced stage NSCLC patients vs healthy controls
Design
Case-control study
Authors
Loading...
Lower IGF-1 levels and ratio were associated with advanced NSCLC and histologic subtype; leaves open diagnostic utility pending prospective validation.
Case-Control (n=80)
Yes
Are pretreatment serum levels of IGF-1 and IGFBP-3 altered in men with advanced non-small cell lung cancer compared to healthy controls?
Absolute Event Rate: 104.7% vs 132.4%
p-value: p=0.025
Pretreatment serum levels of IGF-1 and the IGF-1/IGFBP-3 ratio are significantly lower in men with advanced NSCLC and may serve as useful diagnostic markers.
Çolak et al. (2012) conducted a case-control in Advanced Non-Small Cell Lung Cancer (n=80). Advanced non-small cell lung cancer vs. Healthy controls was evaluated on Pretreatment serum IGF-1 levels (ng/ml) (p=0.025). Pretreatment serum IGF-1 levels were significantly lower in men with advanced non-small cell lung cancer compared to healthy controls (104.7 vs 132.4 ng/ml, p=0.025).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: